Navigation Links
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN 918864)

AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a developer of novel cancer therapeutics, will be presenting a scientific poster at the Fourth International Conference on Tumor Microenvironment, which runs from March 6th to 10th in Florence, Italy.

The conference, hosted by the International Cancer Microenvironment Society, is a premier gathering of international cancer researchers who seek to develop cancer therapies targeting microenvironmental factors that control tumor growth and metastasis.

The poster, titled "L-DOS47 - a tumor microenvironment alkalization agent and a novel lung adenocarcinoma specific therapeutic candidate," provides a summary of selected L-DOS47 previously announced findings. Included in the poster are laboratory data showing the ability of L-DOS47 to bind to and destroy lung cancer cells alone and synergistically with selected chemotherapeutic drugs. Also being presented are mass tissue sample screening data, which show that L-DOS47 binds not only to primary lung adenocarcinoma tissues preferentially over a host of other cancerous or normal tissues, but also to metastasized cells in lymph nodes. The poster also highlights the ability of L-DOS47 to localize and concentrate in tumor tissues specifically following injection into laboratory animals

A copy of the poster will be available on Helix's website for download at http://www.helixbiopharma.com.


For additional information on the Tumor Microenvironment conference, please visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html

About L-DOS47

L-DOS47 combines Helix's proprie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Acquire Exclusive Rights to Gastrin Based Therapies Program for ... ... TORONTO, March 13 Eli Lilly,and Company (NYSE: LLY ) ... two companies have entered into a licensing,and collaboration agreement granting Lilly ...
... KANSAS CITY, Mo., March 13 Synbiotics Corporation ... the Food & Drug,Administration (FDA) for the use ... in humans. This represents Synbiotics first foray into ... Synbiotics,initial intent to market this product itself to ...
Cached Medicine Technology:Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 2Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 3Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 4Synbiotics Corporation Announces Human Submission for FluDetect(R) 2
(Date:9/2/2015)... Boston, MA (PRWEB) , ... September 02, 2015 ... ... reports covering healthcare innovation and investment, announced the two leaders who will deliver ... Boston on November 3, at the Mandarin Oriental Hotel in Boston. , Larry ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and ... mixed documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps ... to reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... obesity being so much in the center of attention now ... cute, chubby babies might actually be too fat //for their ... crafted message that are coming from several top health groups, ... Control and Prevention and the American Academy of Pediatrics as ...
... to an outbreak of mosquito-borne encephalitis B in China, the ... to the 26 people already killed by the disease. ... infected with the disease and 40 of them have died ... in the first six months of 2006. But the newspaper ...
... a study published in the August issue of the Journal, ... have found //that certain risks factors put people younger than ... The findings were based on the study done on ... of people over 60. ,Peripheral vascular disease ...
... disclosed that a specific variety of adult ... neurons or other// types of tissue depending on the ... ,The researchers found that mesenchymal stem cells, which are ... clues from their local environment, allowing a transformation into ...
... exempting mental health units from the ban on smoking ... in the health of people// suffering mental ailments. Smoking ... premature death in the United Kingdom, with nearly 106,000 ... , ,The Health Act 2006 will make ...
... small study revealed that botox injections can help in healing ... Sherris, professor and chair of the department of otolaryngology at ... He said ” This is the first medication found to ... of Mayo Clinic Proceedings. ,The study was conducted ...
Cached Medicine News:Health News:Chubbiness In Babies Might Not Be A Cute Sign 2Health News:Adult stem cells are sensitive to responses from the environment 2Health News:Smoking Ban should Include Mental Health Units 2
Inquire...
... K2 / gel tubes are for ... molecular diagnostics and for viral load ... blood remain stable at room temperature ... optimal results, it is recommended to ...
Glass Whole Blood Tube with K3EDTA...
... transglutaminase (tTg) is a ubiquitous enzyme ... Tissue transglutaminase is also the specific ... endomysial antibody immunofluorescence (EMA) tests (Bio-Rad ... IgA and,IgG serologic tests are highly ...
Medicine Products: